Enterovirus D68-Associated Acute Respiratory Illness - New Vaccine Surveillance Network, United States, July-October, 2017 and 2018.

Research paper by Stephanie A SA Kujawski, Claire M CM Midgley, Brian B Rha, Joana Y JY Lively, W Allan WA Nix, Aaron T AT Curns, Daniel C DC Payne, Janet A JA Englund, Julie A JA Boom, John V JV Williams, Geoffrey A GA Weinberg, Mary A MA Staat, Rangaraj R Selvarangan, Natasha B NB Halasa, Eileen J EJ Klein, et al.

Indexed on: 28 May '19Published on: 29 Mar '19Published in: MMWR. Morbidity and mortality weekly report


In the fall of 2014, an outbreak of enterovirus D68 (EV-D68)-associated acute respiratory illness (ARI) occurred in the United States (1,2); before 2014, EV-D68 was rarely reported to CDC (2,3). In the United States, reported EV-D68 detections typically peak during late summer and early fall (3). EV-D68 epidemiology is not fully understood because testing in clinical settings seldom has been available and detections are not notifiable to CDC. To better understand EV-D68 epidemiology, CDC recently established active, prospective EV-D68 surveillance among pediatric patients at seven U.S. medical centers through the New Vaccine Surveillance Network (NVSN) (4). This report details a preliminary characterization of EV-D68 testing and detections among emergency department (ED) and hospitalized patients with ARI at all NVSN sites during July 1-October 31, 2017, and the same period in 2018. Among patients with ARI who were tested, EV-D68 was detected in two patients (0.8%) in 2017 and 358 (13.9%) in 2018. Continued active, prospective surveillance of EV-D68-associated ARI is needed to better understand EV-D68 epidemiology in the United States.